Notably most of the predicted deleterious/possibly damaging variants we identified did not exert a significant effect on deubiquitinase activity (Fig. 1B) suggesting that weaker alleles, or variants that may influence BAP1 beyond its role as a deubiquitinase, may underlie some of the cancer incidence in mutation carriers. This evidence concerns the gene BAP1 and cancer.